These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33340471)

  • 1. Rapid drug access and scientific rigour: a delicate balance.
    The Lancet Neurology
    Lancet Neurol; 2021 Jan; 20(1):1. PubMed ID: 33340471
    [No Abstract]   [Full Text] [Related]  

  • 2. Alzheimer disease: Anti-Aβ antibody treatment shows promise in Alzheimer disease.
    Fyfe I
    Nat Rev Neurol; 2016 Oct; 12(10):554-5. PubMed ID: 27632905
    [No Abstract]   [Full Text] [Related]  

  • 3. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 4. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 5. Alzheimer's drugs take a new tack.
    Callaway E
    Nature; 2012 Sep; 489(7414):13-4. PubMed ID: 22962697
    [No Abstract]   [Full Text] [Related]  

  • 6. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 7. Bapineuzumab in Alzheimer's disease: where now?
    Wilcock GK
    Lancet Neurol; 2010 Feb; 9(2):134-6. PubMed ID: 20129159
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody drugs for Alzheimer's show glimmers of promise.
    Reardon S
    Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602
    [No Abstract]   [Full Text] [Related]  

  • 9. Doubts persist for claimed Alzheimer's drug.
    Servick K
    Science; 2019 Dec; 366(6471):1298. PubMed ID: 31831649
    [No Abstract]   [Full Text] [Related]  

  • 10. Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy.
    Greenberg SM; Frosch MP
    Neurology; 2011 Mar; 76(9):772-3. PubMed ID: 21357829
    [No Abstract]   [Full Text] [Related]  

  • 11. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 12. The Future of Anti-Amyloid Trials.
    Aisen PS; Cummings J; Doody R; Kramer L; Salloway S; Selkoe DJ; Sims J; Sperling RA; Vellas B
    J Prev Alzheimers Dis; 2020; 7(3):146-151. PubMed ID: 32463066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on trial death stokes Alzheimer's drug fears.
    Piller C
    Science; 2023 Apr; 380(6641):122-123. PubMed ID: 37053319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.
    Musiek ES; Gomez-Isla T; Holtzman DM
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585
    [No Abstract]   [Full Text] [Related]  

  • 15. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
    Dunn B; Stein P; Cavazzoni P
    JAMA Intern Med; 2021 Oct; 181(10):1276-1278. PubMed ID: 34254984
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The search for Alzheimer disease therapeutics - same targets, better trials?
    Rafii MS; Aisen PS
    Nat Rev Neurol; 2020 Nov; 16(11):597-598. PubMed ID: 32963375
    [No Abstract]   [Full Text] [Related]  

  • 19. Amyloid antibody therapy for early-stage Alzheimer's disease: a critical review of three recent trials.
    Guiloff AE; Rudge P
    J Neurol; 2024 May; 271(5):2914-2916. PubMed ID: 38613568
    [No Abstract]   [Full Text] [Related]  

  • 20. Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business.
    Aisen PS; Raman R
    J Prev Alzheimers Dis; 2020; 7(3):195-196. PubMed ID: 32463073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.